Table 1. Characteristics of included studies.

NR: Not reported

Author	Year	Therapy	Doses	Sample Size	Follow-up Duration	Age (Years)	Males  (n)	Diabetes Duration (Years)
Dahl et al [13]	2022	Add-on therapy	5 mg	116	40 Weeks	62	61	14.1
			10 mg	119		60	72	12.6
			15 mg	120		61	65	13.7
Frias et al [14]	2018	Add-on therapy	5 mg	55	26 Weeks	57.9	34	8.9
			10 mg	51		56.5	30	7.9
			15 mg	53		56	22	8.5
Frias et al [15]	2021	Add-on therapy	5 mg	470	40 Weeks	56.3	220	9.1
			10 mg	469		57.2	238	8.4
			15 mg	470		55.9	214	8.7
Gao et al [16]	2023	Add-on therapy	5 mg	230	40 Weeks	53.1	134	7.4
			10 mg	228		53.5	126	7.9
			15 mg	229		54.3	129	7.6
Inagaki et al [17]	2022	Monotherapy	5 mg	159	52 Weeks	NR	NR	NR
			10 mg	158
			15 mg	160
Ludvik et al [18]	2021	Add-on therapy	5 mg	358	52 Weeks	57.2	200	8.5
			10 mg	360		57.4	195	8.4
			15 mg	359		57.5	194	8.5
Prato et al [19]	2021	Add-on therapy	5 mg	329	52 Weeks	62.9	198	9.8
			10 mg	328		63.7	209	10.6
			15 mg	338		63.7	203	10.4
Rosenstock et al [20]	2021	Monotherapy	5 mg	121	40 Weeks	54.1	56	4.6
			10 mg	121		55.8	72	4.9
			15 mg	121		52.9	63	4.8